Patent Row

  • Relief for Pfizer on anticancer drug June 4, 2013

    Chennai: In a relief to pharma major Pfizer, the Intellectual Property Appellate Board in Chennai has set aside the revocation of the patent of the company's anticancer drug 'Sutent'. The Board has asked the Patent Office to consider the entire matter afresh in a timebound manner, which had twice revoked...
  • Patent row: HC refuses interim relief to Merck April 5, 2013

    New Delhi: The Delhi High Court on Friday refused to grant interim relief on a patent row to US pharmaceuticals major Merck Sharp and Dohme (MSD) which sought a restraint on Indian firm Glenmark Pharmaceuticals manufacturing and marketing antidiabetes drugs Zita and ZitaMet. Justice Rajiv Sahai Endlaw dismissed the interim...
  • 'Has to be a balance between innovation, affordability of drugs' April 1, 2013

    After the Supreme Court dismissed Swiss pharma company Novartis' plea for a patent on its cancer drug Glivec, pharma expert vikas Dandekar said, "This will be a far reaching decision. Innovation on one side, access and affordability on the other side. The balance has to be done". ...
  • Will now invest in India 'cautiously', says Novartis April 1, 2013

    Mumbai: Pharmaceutical giant Novartis on Monday termed the Supreme Court's judgement of not granting a patent to its cancer drug Glivec as "disappointing" and warned that though it will continue to introduce new products in India, it will now invest "cautiously". In a landmark verdict, the apex court dismissed the...
  • 'SC ruling discourages innovative drug discovery' April 1, 2013

    New Delhi: Swiss pharmaceutical company Novartis, which lost its battle for patent on its cancer drug Glivec in India on Monday, said the Supreme Court's ruling discourages innovative drug discovery and is a setback for patients. "Novartis has never been granted an original patent for Glivec in India. We strongly believe...
  • SC verdict on Novartis's cancer drug Glivec today April 1, 2013

    New Delhi: The Supreme Court on Monday is likely to pronounce its verdict in the much awaited patent case involving Glivec the anticancer drug manufactured by Swiss pharmagiant Novartis priced at a whopping Rs 1.2 lakhs for a monthly dosage. The case dates back to India's denial of...